Dr. Mayock's basic research interests include evaluation of the effects of fetal and neonatal drug (alcohol, morphine) exposure on fetal, neonatal and adult cerebrovascular function. Dr. Mayock's clinical research interests include evaluation of therapies that potentially may improve the outcomes in infants at risk for neurodevelopmental impairment, and treatments that may alter the likehood of developing Bronchopulmonary Dysplasia such as inhaled nitric oxide and late surfactant treatments.
In collaboration with Drs. Juul and Gleason, he is evaluating whether high dose erythropoietin treatment has neuroprotective effects in preterm and term infants. In collaboration with Dr. Meghan Delaney, he is exploring different methods of protecting infants from transfusion related CMV disease.